Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenue		$ 28,833	$ 38,025	$ 485,424
Operating expenses:
Royalty fees		0	0	66,436
Research and development	[1]	167,259	175,658	107,879
Sales and marketing	[1]	12,779	14,180	11,270
General and administrative	[1]	72,711	60,999	55,485
Depreciation, amortization, and impairment		90,850	24,395	27,843
Total operating expenses		343,599	275,232	268,913
Income (loss) from operations		(314,766)	(237,207)	216,511
Other (income) expense
Interest income		(38,473)	(42,247)	(16,079)
Grants and incentives		(13,620)	(14,155)	(10,554)
Other (Note 15)		(62,278)	(6,776)	4,045
Total other income		(114,371)	(63,178)	(22,588)
Net earnings (loss) before income tax		(200,395)	(174,029)	239,099
Income tax (recovery) expense		(37,538)	(27,631)	80,580
Net earnings (loss)		(162,857)	(146,398)	158,519
Foreign currency translation adjustment		(2,658)	(329)	(1,671)
Comprehensive income (loss)		$ (165,515)	$ (146,727)	$ 156,848
Net earnings (loss) per share
Basic (in dollars per share)		$ (0.55)	$ (0.51)	$ 0.56
Diluted (in dollars per share)		$ (0.55)	$ (0.51)	$ 0.50
Weighted-average common shares outstanding
Basic (in shares)		294,327,532	289,166,486	285,056,606
Diluted (in shares)		294,327,532	289,166,486	314,827,255
Research fees
Revenues:
Total revenue		$ 26,284	$ 35,556	$ 40,802
Licensing revenue
Revenues:
Total revenue		1,049	969	696
Milestone payments
Revenues:
Total revenue		1,500	1,500	900
Royalty revenue
Revenues:
Total revenue		$ 0	$ 0	$ 443,026

[1] Exclusive of depreciation, amortization, and impairment